期刊文献+

左西孟旦治疗射血分数降低充血性心力衰竭急性加重期的临床研究 被引量:3

Effect of levosimendan on patients with acute congestive heart failure with reduced ejection fraction
下载PDF
导出
摘要 目的评价左西孟旦在射血分数降低充血性心力衰竭急性加重期的疗效及安全性。方法入选60例慢性充血性心力衰竭急性加重期的患者,随机分为对照组30例和治疗组30例。对照组以洋地黄类、ACEI/ARB、利尿剂、硝酸酯类等药物常规治疗,治疗组在对照组的治疗基础上加用左西孟旦,10 d后比较2组心功能分级、N末端B型利钠肽原(NT-pro BNP)血浆浓度、左室射血分数(LVEF)、舒张期末左室内径(LVDd)等指标。结果治疗10 d后2组心功能均有显著改善,血压、心率、LVDd下降、NT-pro BNP血浆浓度降低,LVEF升高,治疗前后差异均有统计学意义(P<0.05);与对照组相比,治疗组心率、NT-pro BNP血浆浓度、LVDd降低、LVEF升高更显著(P<0.05)。2组患者在治疗期间未发现有明显不良反应。结论短期应用左西孟旦治疗射血分数降低充血性心力衰竭急性加重期是安全有效的。 Objective To determine the short-term effect of levosimendan on patients with acute congestive heart failure with reduced ejection fraction. Methods A total of 60 patients who met the inclusion criteria were recruited and randomly divided into a group with levosimendan plus conventional therapy(group A), or a group with conventional therapy only(group B), 30 patients in each group. The concentration of NT-proBNP in the plasma, the clinical efficacy of treatment, the left ventricular ejection fraction(LVEF), and Left ventricular diastolic diameter(LVDd) were measured before and 10 days after the treatment. Results Statistically significant difference of plasma NT-proBNP concentration, LVDd, and LVEF were observed between before and after the treatment in both groups(P〈0.05). The plasma NT-proBNP concentration and LVDd in group A was decreased and LVEF in group A increased significantly compared with that of the group B(P〈0.05). Both significant effective rate and total effective rate of group A were higher than those of the group B(P〈0.05). Conclusion Levosimendan shows good short-term clinical effect in improving acute heart failure patients with reduced ejection fraction by reducing the plasma level of NT-proBNP and improving the left ventricular systolic function.
出处 《中南药学》 CAS 2015年第6期654-656,共3页 Central South Pharmacy
关键词 左西孟旦 射血分数降低 充血性心力衰竭 疗效 levosimendan reduced ejection fraction acute congestive heart failure clinical effect
  • 相关文献

参考文献10

  • 1Yancy CW,Jessup M,Bozkurt B,et al.2013 ACCF/AHA guidline for the management of heart failure:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2013,62(16):147-239.
  • 2无.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095. 被引量:3693
  • 3程康安,吴宁.中国部分地区1980、1990、2000年慢性心力衰竭住院病例回顾性调查[J].中华心血管病杂志,2002,30(8):450-454. 被引量:362
  • 4Dickstein K,Cohen-Solal A,Filippatos G,et al.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008.The task force for the diagnosis and treatment of acute and Chronic Heart Failure.2008 of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association of the ESC(HFA)and endorsed by the European Society of Intensive Care Medicine(ESICM)[J].Eur J Heart Fail,2008,10(10):933-989.
  • 5Pathak A,Lebrin M,Vaccaro A,et al.Pharmacology of levosimendan:inotropic,vasodilatory and cardioprotective effects[J].J Clin Pharm Ther,2013,38(5):341-349.
  • 6Nieminen MS,Fruhwald S,Heunks LM,et al.Levosimendan:current data,clinical use and future development[J].Heart Lung Vessel,2013,5(4):227-245.
  • 7Follath F,Cleland JG,Just H,et al.Effi cacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure(the LIDO study):a randomized double-blind trial[J].Lancet,2002,360(9328):196-202.
  • 8Silva-Cardso J,Ferreira J,Oliveira-Soares A,et al.Effectiveness and satety of levosimendan in clinical practice[J].Rev Port Canliol,2009,28(2):143-154.
  • 9张宇辉,张健,卿恩明,黎辉,孙英贤,张麟,白小涓,刘文娴,姜一农,曲鹏,韦丙奇,周琼,黄燕.国产左西孟旦对比多巴酚丁胺治疗急性失代偿性心力衰竭[J].中华心血管病杂志,2012,40(2):153-156. 被引量:46
  • 10周世彦,张鸽,马志强.左西孟旦及其活性代谢物OR-1896的作用机制研究进展[J].中南药学,2006,4(1):54-57. 被引量:2

二级参考文献73

  • 1王方正,张澍,黄德嘉,华伟,孙宝贵,沈法荣,吴书林,王建安,方全,吴立群,王景峰,王冬梅,郭涛,陈新,中华医学会心电生理和起搏分会心脏再同步治疗专家工作组.心脏再同步治疗慢性心力衰竭的建议[J].中华心律失常学杂志,2006,10(2):90-102. 被引量:91
  • 2[1]Greenberg B,Borghi C,Perrone S.Pharmacotherapeutic approaches for decompensated heart failure:a role for the calcium sensitiser,levosimendan?[J].The European Journal of Heart Failure,2003,5(1):13-21.
  • 3[2]Papp Z,Csapo K,Pollesello P,et al.Pharmacological mechanisms contributing to the clinical efficacy of levosimendan[J].Cardiovasc Drug Rev,2005,23(1):71-98.
  • 4[3]Lepran I,Papp JG.Effect of long-term oral pretreatment with levosimendan on cardiac arrhythmias during coronary artery occlusion in conscious rats[J].European Journal of Pharmacology,2003,464(2~3):171-176.
  • 5[4]Auslender M.New drugs in the treatment of heart failure[J].Progress in Pediatric Cardiology,2000,12(1):119-124.
  • 6[5]Ajiro Y,Hagiwara N,Katsube Y,et al.Levosimendan increases L-type Ca2+ current via phosphodiesterase-3 inhibition in human cardiac myocytes[J].European Journal of Pharmacology,2002,435(1):27-33.
  • 7[6]Takahashi R,Talukder MA,Endoh M.Inotropic effects of OR-1896,an active metabolite of levosimendan,on canine ventricular myocardium[J].European Journal of Pharmacology,2000,400(1):103-112.
  • 8[7]Haikala H,Pollesello P.Calcium sensitivity enhancers[J].Idrugs,2000,3(10):1199-1205.
  • 9[8]Avgeropoulou C,Andreadou I,Markantonis-Ky roudiss,et al.The Ca2+-sensitizer levosimendan improves oxidative damage,BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine[J].Eur J Heart Fail,2005,7(5):882-887.
  • 10[9]Pataricza J,Hohn J.Comparison of the vasorelaxing effect of cromokalim and the new inodilator,levosimendan,in human isolated portal vein[J].J Pharm Pharmacol,2000,52(2):213-219.

同被引文献26

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部